Thank you for Subscribing to Life Science Review Weekly Brief
There is a forecast that the bioanalytical services market will grow at a CAGR of 8.2% from 2022 to 2030, representing a 7.7 percent increase in value.
FREMONT, CA: The rise in infectious diseases is one of the major factors contributing to the resurgence of the bioanalytical services market. There is a growing trend among pharmaceutical companies to collaborate with research institutes to provide the necessary bioanalytical services. Pre-clinical tests, fluid or specimen testing, clinical sample analysis, and investigations of the presence of viruses in the body, amongst other things, constitute the component of bioanalytical services. This has created significant growth opportunities for market contributors in the wake of the global pandemic due to these services. Bioanalytical services played a significant role during the drug investigation and vaccination program for COVID-19. An ongoing analysis, a vaccine testing procedure, a drug inspection procedure, technological advancements in pharmaceutical companies, and state of the art in bioanalytical services are creating revenue opportunities in a market experiencing a pandemic.
Market challenges in bioanalytical services
A shortage of highly skilled and productive workforce is one of the biggest challenges for many bioanalytical service providers. Increasing demand for bioanalytical testing services requires the development of innovative solutions in bioanalytical laboratories and research centers.
The government invests in training, webinars, and scientific publications for students and graduates to educate and keep up with the latest trends.
For example, new technologies, better tools, and better equipment are needed for accurate sample analysis to minimize the complexities in bioanalytics.The increasing role of contract research organizations (CROs)
Bioanalytical services market to reach $12.34 billion by 2031. New technologies and applications are being experimented with by manufacturers. A growing number of standards and escalating complexity are driving the market. R&D outsourcing is a pharmaceutical strategy company use to stay ahead of the competition and generate more revenue. CRO scope and expansion are largely driven by research and development expenditures, bioinformatics advances, and government healthcare expenditures. A highly demanding branch of medicine is oncology, which deals with cancer diagnosis and treatment. Big Data and artificial intelligence also drive growing demand for bioanalytical services.
Bioanalysis and Infectious Diseases
Pharmaceuticals, biopharmaceuticals, vaccines, and biosimilars have all gained momentum due to the Coronavirus outbreak. COVID-19 pandemic mitigation relied heavily on bioanalytical services. Bioanalytical testing services are advantageous these days, such as preventing and controlling future waves of SARS-CoV-2, HIV, etc. The demand for small molecular and large molecular bioanalytical services has increased, including electrophoresis, tissue bioanalysis, immunochemistry, electrochemical and titrimetric assays, and immunoassays. Bioanalytical services manufacturers have lucrative revenue opportunities due to high demand.